Compare GSIW & SCYX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | GSIW | SCYX |
|---|---|---|
| Founded | 2016 | 1999 |
| Country | Hong Kong | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 28.6M | 26.3M |
| IPO Year | 2023 | 2014 |
| Metric | GSIW | SCYX |
|---|---|---|
| Price | $0.13 | $0.60 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 299.7K | ★ 366.6K |
| Earning Date | 01-01-0001 | 11-05-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $5,368,221.00 | $2,932,000.00 |
| Revenue This Year | N/A | $167.73 |
| Revenue Next Year | N/A | $290.78 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 283.23 | N/A |
| 52 Week Low | $0.09 | $0.57 |
| 52 Week High | $1.79 | $1.49 |
| Indicator | GSIW | SCYX |
|---|---|---|
| Relative Strength Index (RSI) | 39.19 | 33.43 |
| Support Level | $0.13 | $0.58 |
| Resistance Level | $0.14 | $0.63 |
| Average True Range (ATR) | 0.01 | 0.02 |
| MACD | -0.00 | -0.00 |
| Stochastic Oscillator | 12.65 | 18.76 |
Garden Stage Ltd is a Hong Kong-based financial services provider principally engaged in the provision of placing and underwriting services; securities dealing and brokerage services; and asset management services. Its business is carried out through its wholly owned Operating Subsidiaries: I Win Securities, which is licensed to conduct Type 1 (dealing in securities) regulated activities under the SFO in Hong Kong; and I Win Asset Management, which is licensed to conduct Type 4 (advising on securities) and Type 9 (asset management) regulated activities under the SFO in Hong Kong.
SCYNEXIS Inc is a drug development company that focuses on the development and commercialization of novel anti-infectives to address unmet therapeutic needs. It is engaged in developing a product candidate, ibrexafungerp which is a novel oral and intravenous (IV) drug for the treatment of several fungal infections, including serious and life-threatening invasive fungal infections. The ibrexafungerp is a novel and structurally distinct triterpenoid glucan synthase inhibitor that is effective in vitro and in vivo against broad range of Candida and Aspergillus species, including drug-resistant strains as well as Pneumocystis, Coccidioides, Histoplasma and Blastomyces genera and some common mucorales species.